America Wants to Make More Generic Drugs. India Shows Why That’s Hard.

Live updates

1. 2h ago

   U.S. Exempts Generic Drugs From Tariffs

   The United States has exempted generic drugs from new pharmaceutical tariffs, highlighting the severe challenges involved in shifting low-cost medicine production back to domestic soil. President Donald Trump previously announced plans for tariffs of 25% or higher on pharmaceutical and semiconductor imports, creating significant uncertainty for the Indian pharmaceutical industry. While the White House has laid the groundwork to reshore the production of 86 essential medicines, the heavy reliance on overseas manufacturing persists. India's vast cost advantages and massive production output remain central to the global drug supply chain, even as broader tariff policies threaten industry growth targets.

   Why it matters

   Efforts by the United States to onshore the manufacturing of essential medicines collide with a deeply entrenched reliance on overseas generic drug producers. India serves as a primary hub for affordable pharmaceuticals, supplying a major share of medications consumed in America. Imposing steep import levies risks driving up medication costs for patients and providers while failing to instantly replicate complex foreign supply chains domestically.

   What is confirmed

   • President Donald Trump announced plans to impose a tariff of 25% or higher on semiconductor and pharmaceutical imports.
   • The White House laid the groundwork to reshore the production of 86 essential medicines.
   • The United States exempted generic drugs from new pharmaceutical tariffs.

   Still unconfirmed

   • India's pharmaceutical industry now expects to reach $80 billion to $90 billion by 2030, falling short of its $130 billion target due to tariff uncertainty.
   • Dr. Reddy's Hyderabad plant employs about 1,900 workers and produces more than 100 generic drugs.

   What to watch next

   • Implementation details and final timelines for the reshoring of the 86 essential medicines.
   • Further policy adjustments regarding pharmaceutical and specialty drug tariffs from the White House.
   Sources used for this update (12)

   1. The New York Times — America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
   2. CNN — Trump’s huge tariffs on some drugmakers could end up backfiring | CNN Business
   3. Fierce Pharma — White House lays groundwork to reshore production of 86 essential medicines
   4. 25newsnow.com — Peoria pharmacist says new drug tariffs could raise costs for imported medications
   5. WSJ — Opinion | The U.S. Tariff Attack on U.S. Biotech
   6. woodsmokeblog.wordpress.com — Peruvian notes 1 ~ transnational support – woodsmokeblog
   7. housedemocrats.wa.gov — Friday, October 2 – Washington State House Democrats
   8. jen.jiji.com — Rain, thunderstorms and falling temperatures: the weather turning point in Italy
   9. tfiglobalnews.com — Speciality Drug Tariffs: US Spares India and 19 Nations
   10. www.zetik.com — U.S. Exempts Generic Drugs From 100% Pharma Tariffs as India ...
   11. indiawest.com — India’s Generic Pharma Exports To US Face Threat With ...
   12. indiawest.com — India's Pharma Growth Falls Short Amid Tariff Concerns
   confidence 90%